GSK (GSK) said Wednesday it has completed the acquisition of Nuvalent (NUVL), a Boston-based clinical-stage biopharmaceutical company, in a transaction with an aggregate equity value of about $10.6 billion.

The transaction, which represents a net investment of about $9.4 billion after accounting for acquired cash, was finalized through a tender offer for all outstanding Nuvalent shares.

The deal adds three lung cancer assets to GSK's oncology portfolio, according to a statement.

Price: 51.55, Change: +0.30, Percent Change: +0.58